Digestive Endoscopy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2023-10-27 ms3000001308631299 来自江苏省

投稿两天，就Under Review，过了1天发邮件让我修改格式重投

82 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2023-10-27 14885ad9m72(暂无昵称) 来自江苏省

外科手术可以投吗

84 0

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2022-03-14 zhangyuanyuan4968

投稿3天，Under Review有戏吗？

95 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2021-10-11 1484bf18m20暂无昵称

中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少

112 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2023-04-18 ms2000000147841561 来自河北省

偏重的研究方向：小肠疾病
经验分享：小肠疾病

103 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2019-01-21 12129bc6m55暂无昵称

请问可以有两个共同通讯作者吗

256 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2021-09-02 alicehaibo

刚刚投稿，随后会分享心得经验

118 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2021-04-06 ms2000000713462597

审稿速度:1.0 | 投稿命中率:5.0
经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies.

109 0

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2020-12-18 12107b02m29(暂无昵称)

审稿速度:1.0 | 投稿命中率:5.0
经验分享：2天拒稿。拌面有限，不够优先

151 0

[GetPortalCommentsPageByObjectIdResponse(id=2165148, encodeId=db0a2165148b8, content=投稿两天，就Under Review，过了1天发邮件让我修改格式重投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4898542576, createdName=ms3000001308631299, createdTime=Fri Oct 27 00:53:21 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165283, encodeId=4f8a2165283ac, content=外科手术可以投吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e435309968, createdName=14885ad9m72(暂无昵称), createdTime=Fri Oct 27 15:19:40 CST 2023, time=2023-10-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1202446, encodeId=3d64120244600, content=投稿3天，Under Review有戏吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krrGr1HkL2Gl7ibKMfiaxFDfk8ooX2wKVqzMMmDYZEhyD6bNYCouCkTg1zL6EhBr4cRPwH5icBgibpdbQ/0, createdBy=cc4f2072535, createdName=zhangyuanyuan4968, createdTime=Mon Mar 14 12:37:33 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059557, encodeId=e64a105955e78, content=中了一篇review，初审1个多月，reject but resubmit，其实就是大修，中间有事拖延了，一直到两个月deadline的时候才修回，三周后意见变为revision，一周后修回，持续两周以后accept。只能说日本人做事很严谨，而且实际要查pibmed每年中国人的文章很少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5bae5283999, createdName=1484bf18m20暂无昵称, createdTime=Mon Oct 11 19:33:48 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126744, encodeId=9c202126e442c, content=偏重的研究方向：小肠疾病 经验分享：小肠疾病, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bf26472850, createdName=ms2000000147841561, createdTime=Tue Apr 18 14:03:09 CST 2023, time=2023-04-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=565827, encodeId=628956582e2b, content=请问可以有两个共同通讯作者吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=256, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9e032233108, createdName=12129bc6m55暂无昵称, createdTime=Mon Jan 21 00:00:00 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013662, encodeId=f04d10136623e, content=刚刚投稿，随后会分享心得经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74e74164, createdName=alicehaibo, createdTime=Thu Sep 02 08:44:05 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954229, encodeId=b2e8954229f2, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：交稿一个星期后被拒，版面有限，不够优先。We receive far more manuscripts than our reviewers can handle and must reject some papers based on the priority for publication. Decisions regarding priority are made based on the subject matter, the relevance to our readership, study design, originality and the submission of other similar studies. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74665434563, createdName=ms2000000713462597, createdTime=Tue Apr 06 15:55:15 CST 2021, time=2021-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=909099, encodeId=7434909099e1, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：2天拒稿。拌面有限，不够优先, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51c02222748, createdName=12107b02m29(暂无昵称), createdTime=Fri Dec 18 12:43:57 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589488, encodeId=a9bb58948825, content=你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, beContent=hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/03/30/bf4180871ccc0aff6cf2316cb46cb0c6.jpg, createdBy=a1525313701, createdName=1211718581, createdTime=Wed Apr 22 00:00:00 CST 2020, time=2020-04-22, status=1, ipAttribution=)]

2020-04-22 1211718581

你好请问参考文献样式有endnote 格式吗在指南中没有找到可以下载的版式hepati 2017-04-03 20:32:00 发表:
2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。

hepati 2017-04-03 20:32:00 发表: 2011年中过一篇，当时杂志还邮寄一份杂志给我，这我发表的SCI杂志中唯一收到的邮寄杂志。

163 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务